Global Actinic Keratosis Treatment Market Size study, By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class (Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers, Others), By End-use (Hospitals, Private Clinics, H

Global Actinic Keratosis Treatment Market Size study, By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class (Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers, Others), By End-use (Hospitals, Private Clinics, Homecare, Others), and Regional Forecasts 2022-2028

Global Actinic Keratosis Treatment Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. The Actinic Keratosis refers to an abnormal growth of cells caused by long-term damage from the sun. In this condition skin develops rough, scaly patch. face, lips, ears, forearms, scalp, neck or back of the hands are largely affected by Actinic Keratosis. The rising prevalence of actinic keratosis disease and growing awareness towards the disease as well as recent strategic initiatives from leading market players are factors that are accelerating the global market demand. For instance, according to Skin Cancer Foundation, USA – as of 2020, Actinic keratosis is the most prevalent precancer and it affects around 58 million Americans. Furthermore, leading market players are coming up with innovative treatment products to leverage the increasing demand for actinic keratosis treatment solutions. For instance, in June 2020, India based Sun Pharmaceutical Industries Ltd. launched Levulan Kerastick. This new product is a topical solution for the treatment of mild to moderate actinic keratosis of the scalp, face, and upper extremities. Moreover, in September 2021, Athenex announced phased Launch of its novel topical microtubule inhibitor named Klisyri® (tirbanibulin) for the treatment of Actinic Keratosis. This new product is approved by the UK Medicines and Healthcare products Regulatory Agency and would be available for prescription in the UK and Germany. Also, rising geriatric population and growing research & development activities in healthcare sector are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high cost associated with treatment of actinic keratosis and complex process of regulatory approvals impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Actinic Keratosis Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing incidences of the diseases and recent regulatory approvals in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the thriving growth of healthcare sector and increasing penetration of leading market players in the region, would create lucrative growth prospects for the global Actinic Keratosis Treatment Market across the Asia Pacific region.

Major market players included in this report are:
Sun Pharmaceutical Industries Ltd.
Novartis AG
GALDERMA
Hill Dermaceuticals, Inc.
Viatris Inc.
Mylan N.V.
Bausch Health Companies, Inc.
LEO Pharma A/S
Almirall, S.A.
Biofrontera AG

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapy
Topical
Surgery
Photodynamic Therapy
By Drug Class
Nucleoside Metabolic Inhibitor
NSAIDs
Immune Response Modifiers
Photoenhancers
Others

By End-use
Hospitals
Private Clinics
Homecare
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Actinic Keratosis Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors



Companies Mentioned

Sun Pharmaceutical Industries Ltd.
Novartis AG
GALDERMA
Hill Dermaceuticals, Inc.
Viatris Inc.
Mylan N.V.
Bausch Health Companies, Inc.
LEO Pharma A/S
Almirall, S.A.
Biofrontera AG

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.